Perindopril Ameliorates Glomerular and Renal Tubulointerstitial Injury in the SHR/N-Corpulent Rat

Hypertension - Tập 30 Số 5 - Trang 1232-1237 - 1997
Manuel T. Velasquez1,2,3,4, John S. Striffler1,2,5,4, A. Abraham6,1,2,4, O. E. Michaelis1,2,7,4, Elizabeth Scalbert1,8,2,4, Nancy Thibault1,2,9,4
1Beltsville Human Nutrition Research Center, Agricultural Research Service, US Department of Agriculture, Beltsville, Md
2From the Departments of Medicine and Pathology, George Washington University Medical Center, Washington, DC; Beltsville Human Nutrition Research Center, Agricultural Research Service, US Department of Agriculture, Beltsville, Md; University of Maryland, College Park, Md; and Cardiorespiratory Department, Institut De Recherches Internationales Servier & Compagnie-Developpement, Paris, France.
3Manuel T. Velasquez From the Departments of Medicine and Pathology, George Washington University Medical Center, Washington, DC
4University of Maryland, College Park, MD
5John S. Striffler From the Departments of Medicine and Pathology, George Washington University Medical Center, Washington, DC
6Andrew A. Abraham From the Departments of Medicine and Pathology, George Washington University Medical Center, Washington, DC
7Otho E. MichaelisIV From the Departments of Medicine and Pathology, George Washington University Medical Center, Washington, DC
8Elizabeth Scalbert From the Departments of Medicine and Pathology, George Washington University Medical Center, Washington, DC
9Nancy Thibault From the Departments of Medicine and Pathology, George Washington University Medical Center, Washington, DC

Tóm tắt

Abstract We compared the effects of long-term treatment with the angiotensin-converting enzyme inhibitor perindopril and triple therapy (hydrochlorothiazide, reserpine, and hydralazine) on the metabolic and renal features in the SHR/N-corpulent (cp) rat, a genetic model of non–insulin-dependent diabetes mellitus and hypertension. Obese male SHR/N-cp rats (4 to 6 weeks old) were fed a 54% carbohydrate diet containing 18% sucrose and 36% starch. After 2 months on the diet, rats were assigned to one of three groups: one group (n=8) received perindopril (PE); the second group (n=8) received triple therapy (TT); and the third group (n=8) did not receive therapy. Treatment was maintained for 3 to 4 months. Body weight, food intake, and fasting levels of serum glucose and insulin did not differ among the three groups. Control rats exhibited progressive proteinuria in parallel with the rise in systolic blood pressure (SBP). Both PE and TT equally lowered SBP to normal levels and reduced proteinuria in treated rats. However, the reduction of proteinuria was greater and more sustained with PE than with TT ( P <.05), whereas the effect of TT on proteinuria was delayed. Plasma renin activity was increased in PE and TT rats compared with control rats ( P <.02). Semiquantitative analysis of renal lesions showed that the percentage of glomeruli with mesangial expansion and sclerosis and the tubulointerstitial score (an index of severity of tubulointerstitial lesions, namely tubular atrophy, inflammatory cellular infiltrates, and interstitial fibrosis) was reduced in both PE and TT rats. However, the reduction of glomerulosclerosis and tubulointerstitial lesions was greater in PE than in TT rats ( P <.01). The percentage of glomerular sclerosis was positively correlated with the severity score of tubulointerstitial lesions ( r =.60, P <.01). We conclude that PE is more effective than TT in halting the progression of proteinuria in the SHR/N-cp rat with non–insulin-dependent diabetes mellitus and hypertension. The antiproteinuric effect of PE is associated with significant reduction in glomerulosclerosis and tubulointerstitial lesions, independent of the effect of treating hypertension.

Từ khóa


Tài liệu tham khảo

Mogensen CE. High blood pressure as a factor in the progression of diabetic nephropathy. Acta Med Scand Suppl.. 1976;602:29-32.

10.1007/BF00276992

10.7326/0003-4819-110-10-795

10.1080/00365517609055274

Christlieb AR Warram JH Krolewski AS Busick EJ Ganda OP Asmal AC Soeldner JS Bradley RF. Hypertension: the major risk factor in juvenile-onset insulin-dependent diabetics. Diabetes. 1981;30(suppl 2):90-96.

10.1136/bmj.285.6343.685

10.1016/S0140-6736(83)92462-5

10.1136/bmj.295.6597.515

10.1056/NEJM198801213180303

10.1056/NEJM198801213180304

10.1111/j.1440-1681.1986.tb02394.x

10.1097/00004872-198812000-00009

10.1016/S0891-6632(87)80079-X

10.7326/0003-4819-118-2-199301150-00009

10.1038/ki.1989.227

10.2337/diab.39.12.1575

10.1038/ki.1992.137

Gambaro G Morbiato F Cicerello E Del Turco M Sartori L D’Angelo A Grepaldi G. Captopril in the treatment of hypertension in type I and type II diabetic patients. J Hypertens. 1985;3(suppl 2):153-154.

10.1007/BF00265402

10.1136/bmj.293.6545.471

10.1056/NEJM199311113292004

Mulec H Johnsen SA Bjork S. Long-term enalapril treatment in diabetic nephropathy. Kidney Int. 1994;45(suppl. 45):S141-S144.

Hansen CT. Two congenic rat strains for nutrition and obesity research. Fed Proc.. 1983;42:537.

10.1093/ajcn/39.4.612

Koletsky S. New type of spontaneously hypertensive rats with hyperlipemia and endocrine gland defects. In: Okamoto K ed. Spontaneous Hypertension: Its Pathogenesis and Complications. Tokyo Japan: Igaku Shoin Ltd; 1972:194-197.

10.1253/jcj.27.282

Michaelis OE IV, Patrick DH, Hansen CT, Canary JJ, Werner RM, Carswell N. Spontaneous hypertensive/NIH-corpulent rat. Animal model for insulin-independent diabetes mellitus (type II). Am J Pathol.. 1986;123:398-400.

10.2337/diab.38.6.679

10.1152/jappl.1973.34.2.279

10.1093/clinchem/20.5.586

Carswell N, Michaelis OE IV, Prather E. Effect of acarbose (BAY-g-5421) on expression of non–insulin-dependent diabetes mellitus in sucrose-fed SHR/N-corpulent rats. J Nutr.. 1989;119:383-394.

10.1210/jcem-29-10-1349

Lowry OH, Rosebrough NJ, Farr AL, Randall RS. Protein measurement with the folinphenol reagent. J Biol Chem.. 1951;123:265-275.

Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest.. 1986;77:125-130.

10.2337/diab.42.4.604

10.2337/diab.8.4.251

Mauer SM Steffes MW Michael AF Brown DM. Studies of diabetic nephropathy in animals and man. 1976;25:850-857.

10.2337/diab.32.2.S79

Steffes MW, Mauer SM. Diabetic glomerulopathy in man and experimental animal models. Int Rev Exp Pathol.. 1984;26:147-175.

10.1096/fasebj.2.8.3282959

10.1016/S0344-0338(80)80051-3

Rasch P. Tubular lesions in streptozotocin diabetic rats. Diabetologia. 1984;27:32-37.

Deckert T, Parving H-H, Thomsen OF, Jorgensen HE, Brun C, Thomsen AC. Renal structure and function in type I (insulin-dependent) diabetic patients. Diabetic Nephropathy. 1985;4:163-168.

10.1172/JCI111523

10.1038/ki.1991.57

Thông tin
Thông tin xuất bản

Hypertension

Tập 30 Số 5

1232-1237

Thông tin tác giả